Preclinical efficacy studies of influenza a haemagglutinin precursor cleavage loop peptides as a potential vaccine

Journal of General Virology

Volumn 92, Issue 5, 2011, Pages 1152-1161

  Miller, Darren S ^a   Finnie, John ^b   Bowden, Timothy R ^c   Scholz, Anita C ^d   Oh, Sawyin ^a   Kok, Tuckweng ^a,b   Burrell, Christopher J ^a,b   Trinidad, Lee ^c   Boyle, David B ^c   Li, Peng ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CSIRO   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; FURIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BODY WEIGHT; CROSS PROTECTION; FEMALE; GALACTOSYLCERAMIDES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HISTOCYTOCHEMISTRY; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; MICROSCOPY; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN PRECURSORS; VACCINES, SUBUNIT; VIRAL LOAD;

MUS;

EID: 79955587657     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.028985-0     Document Type: Article

References (31)

1. Alsharifi, M., Furuya, Y., Bowden, T. R., Lobigs, M., Koskinen, A., Regner, M., Trinidad, L., Boyle, D. B. & Mullbacher, A. (2009). Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS ONE 4, e5336.
2. Au-Yeung, B. B. & Fowell, D. J. (2007). A key role for Itk in both IFN gamma and IL-4 production by NKT cells. J Immunol 179, 111-119.
3. Bendelac, A., Rivera, M. N., Park, S. H. & Roark, J. H. (1997). Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15, 535-562.
4. Bianchi, E., Liang, X., Ingallinella, P., Finotto, M., Chastain, M. A., Fan, J., Fu, T. M., Song, H. C., Horton, M. S. & other authors (2005). Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 79, 7380-7388.
5. Borg, N. A., Wun, K. S., Kjer-Nielsen, L., Wilce, M. C., Pellicci, D. G., Koh, R., Besra, G. S., Bharadwaj, M., Godfrey, D. I. & other authors (2007). CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448, 44-49.
6. Brossay, L., Jullien, D., Cardell, S., Sydora, B. C., Burdin, N., Modlin, R. L. & Kronenberg, M. (1997). Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol 159, 1216-1224.
7. Chen, J., Lee, K. H., Steinhauer, D. A., Stevens, D. J., Skehel, J. J. & Wiley, D. C. (1998). Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95, 409-417.
8. + T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol 171, 3163-3169.
9. Du, W. & Gervay-Hague, J. (2005). Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors. Org Lett 7, 2063-2065.
10. Gazit, R., Gruda, R., Elboim, M., Arnon, T. I., Katz, G., Achdout, H., Hanna, J., Qimron, U., Landau, G. & other authors (2006). Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7, 517-523.
11. Gebe, J. A., Novak, E. J., Kwok, W. W., Farr, A. G., Nepom, G. T. & Buckner, J. H. (2001). T cell selection and differential activation on structurally related HLA-DR4 ligands. J Immunol 167, 3250-3256.
12. Horvath, A., Toth, G. K., Gogolak, P., Nagy, Z., Kurucz, I., Pecht, I. & Rajnavolgyi, E. (1998). A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett 60, 127-136.
13. Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J. & Metzger, D. W. (2001). Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166, 7381-7388.
14. Klenk, H. D., Rott, R., Orlich, M. & Blodorn, J. (1975). Activation of influenza A viruses by trypsin treatment. Virology 68, 426-439.
15. Ko, S. Y., Ko, H. J., Chang, W. S., Park, S. H., Kweon, M. N. & Kang, C. Y. (2005). a-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175, 3309-3317.
16. Kok, T., Mickan, L. D. & Burrell, C. J. (1994). Routine diagnosis of seven respiratory viruses and Mycoplasma pneumoniae by enzyme immunoassay. J Virol Methods 50, 87-100.
17. Lazarowitz, S. G. & Choppin, P. W. (1975). Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68, 440-454.
18. Lennette, E. H. & Schmidt, N. J. (1979). Diagnostic Procedures for: Viral, Rickettsial and Chlamydial Infections. Washington, DC 20005: American Public Health Association, Inc.
19. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103, 383-389.
20. Nishimura, H., Itamura, S., Iwasaki, T., Kurata, T. & Tashiro, M. (2000). Characterization of human influenza A (H5N1) virus infection in mice: neuro-, pneumo- and adipotropic infection. J Gen Virol 81, 2503-2510.
21. Renegar, K. B. & Small, P. A., Jr (1991). Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146, 1972-1978.
22. Renegar, K. B., Small, P. A., Jr, Boykins, L. G. & Wright, P. F. (2004). Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173, 1978-1986.
23. Slingluff, C. L., Jr, Yamshchikov, G., Neese, P., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D., Deacon, D., Hibbitts, S. & other authors (2001). Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7, 3012-3024.
24. Stone, B., Burrows, J., Schepetiuk, S., Higgins, G., Hampson, A., Shaw, R. & Kok, T. (2004). Rapid detection and simultaneous subtype differentiation of influenza A viruses by real time PCR. J Virol Methods 117, 103-112.
25. Tam, J. P. (1994). Immunization with peptide-carrier complexes: traditional and multiple-antigen peptide systems. In Peptide Antigens, a Practical Approach, pp. 83-115. Edited by G. B. Wisdom. Oxford: IRL Press.
26. Thomas, P. G., Keating, R., Hulse-Post, D. J. & Doherty, P. C. (2006). Cell-mediated protection in influenza infection. Emerg Infect Dis 12, 48-54.
27. Treanor, J. (2004). Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 350, 218-220.
28. Veldt, B. J., van der Vliet, H. J., von Blomberg, B. M., van Vlierberghe, H., Gerken, G., Nishi, N., Hayashi, K., Scheper, R. J., de Knegt, R. J. & Vandeneertwegh, A. (2007). Randomized placebo controlled phase I/II trial of a-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 47, 356-365.
29. Wilson, I. A. & Cox, N. J. (1990). Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 8, 737-787.
30. Yen, H. L., Monto, A. S., Webster, R. G. & Govorkova, E. A. (2005). Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192, 665-672.
31. Youn, H. J., Ko, S. Y., Lee, K. A., Ko, H. J., Lee, Y. S., Fujihashi, K., Boyaka, P. N., Kim, S. H., Horimoto, T. & Kweon, M. (2007). A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25, 5189- 5198.